参考文献/References:
［1］ Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods［J］. Int J Cancer, 2019, 144: 1941-1953.
［2］ Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review［J］. J Surg Oncol, 2018, 117: 341-353.
［3］ 安天志，高 嵩，靳 勇，等. 中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南［J］. 介入放射学杂志，2018，27:1117- 1126.
［4］ Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study［J］. Liver Int, 2015, 35: 2155-2166.
［5］ Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features［J］. Gastroenterology, 2017, 153: 812-826.
［6］ Ruiz de Galarreta M, Bresnahan E, Molina-Sanchez P, et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma［J］. Cancer Discov, 2019, 9: 1124-1141.
［7］ Wang YX, De Baere T, Idee JM, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences［J］. Chin J Cancer Res, 2015, 27:96-121.
［8］ Xue J, Ni H, Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Inter Med, 2021, 4: 105-113.
［9］ Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma［J］. Gastroenterology, 2004, 127: S179-S188.
［10］张利捷，梁 斌. 免疫检查点阻断与肝癌化疗栓塞［J］. 介入放射学杂志，2020，29：419-422．
［11］何 旭，占美晓，陆骊工. 肝动脉化疗栓塞治疗肝细胞癌的应用现状与展望［J］. 中华介入放射学电子杂志，2018，6：124-126.
［12］ Takaki H, Imai N, Contessa TT, et al. Peripheral blood regulatory T-cell and type 1 helper T-cell population decrease after hepatic artery embolization［J］. J Vasc Interv Radiol, 2016, 27: 1561-1568.
［13］Guardascione M, Toffoli G. Immune checkpoint inhibitors as monotherapy or within a combinatorial strategy in advanced hepatocellular carcinoma［J］. Int J Mol Sci, 2020, 21: 6302.
［14］ Ma XC, Sun XY, Xie FB, et al. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients［J］. Asia Pac J Clin Oncol, 2022, 18: e515-e523.
［15］ Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor［J］. Immunity, 1999, 11: 141-151.
［16］ Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity［J］. Annu Rev Immunol, 2008, 26: 677-704.
［17］ Kim HD, Song GW, Park S, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma［J］. Gastroenterology, 2018, 155:1936- 1950.
［18］ Kang S, Bai X, Chen SJ, et al. The potential combinational immunotherapies for treatment of hepatocellular carcinoma［J］. J Interv Med, 2019, 2: 47-51.
［19］ Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features［J］. Hepatology, 2016, 64: 2038-2046.
［20］ Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade［J］. J Clin Invest, 2015, 125: 3377- 3383.
［21］黄健翔，骆旭航，龚安安. 卡瑞利珠单抗配合TACE对伴微血管侵犯肝细胞癌患者根治术后血清Egfl7、VEGF、OPN水平及复发率影响的前瞻性研究［J］. 世界华人消化杂志，2021，29：182- 189.
［22］杨秋雨，魏 宁，徐 浩，等. TACE联合卡瑞利珠单抗治疗中晚期肝癌短期疗效及疗效相关性分析［J］. 医学影像学杂志，2021，31：1212-1219．
［23］李伍好. TACE联合卡瑞利珠单抗与单纯TACE治疗中晚期肝癌的对比研究［D］. 蚌埠医学院，2021．
［24］Chao J, Zhu Q, Chen D, et al. Case report: transarterial chemoembolization in combination with tislelizumab downstages unresectable hepatocellular carcinoma followed by radical salvage resection［J］. Front Oncol, 2021, 11: 667555.
［25］ Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma［J］. J Hepatol, 2017, 66: 545-551.
［26］ Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation［J］. J Exp Med, 2014, 211: 781-790.
［27］周 晨，刘家成，石 钦，等. 肝癌分子靶向药物及免疫抑制剂治疗的研究现状及进展［J］. 中华介入放射学电子杂志，2019，7：243-250．
［28］ Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial［J］. J Hepatol, 2016, 64: 1090-1098.
［29］ Zheng L, Fang S, Wu F, et al. Efficacy and safety of TACE combined with sorafenib plus immune checkpoint inhibitors for the treatment of intermediate and advanced TACE-refractory hepatocellular carcinoma: a retrospective study［J］. Front Mol Biosci, 2020, 7: 609322.
［30］ Yang F, Xu GL, Huang JT, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response［J］. Front Immunol, 2022, 13: 847601.
［31］黄 剑，葛乃建，徐 伟，等. TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例［J］. 介入放射学杂志，2021，30：774-779．
［32］刘 金，曹 刚，张根山，等. 卡瑞利珠单抗联合阿帕替尼治疗D-TACE后进展的中晚期肝癌的初步疗效及安全性分析［J］. 中华医学杂志，2021，101：2304-2309．
［33］韩绪生，凌 冰，杨 勇，等. TACE联合阿帕替尼治疗中晚期肝癌的临床研究［J］. 介入放射学杂志，2021，30：941-944．
［34］ Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti- PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study［J］. J Hepatocell Carcinoma, 2021, 8: 1233-1240.
［35］ Pinato DJ, Cortellini A, Sukumaran A, et al. PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma［J］. BMC Cancer, 2021, 21: 301.
相似文献/References:
[1]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(01):543.
[2]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(01):55.
[3]刘 晟,周平盛,沈 强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(01):36.